Regeneron Short Term Investments vs Other Current Liab Analysis
REGN Stock | USD 1,003 2.16 0.22% |
Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Short Term Investments and its Other Current Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Short Term Investments vs Other Current Liab
Short Term Investments vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Short Term Investments account and Other Current Liab. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Regeneron Pharmaceuticals' Short Term Investments and Other Current Liab is 0.94. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Short Term Investments and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Regeneron Pharmaceuticals are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Short Term Investments i.e., Regeneron Pharmaceuticals' Short Term Investments and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.94 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Short Term Investments
Short Term Investments is an item under the current assets section of Regeneron Pharmaceuticals balance sheet. It contains any investments Regeneron Pharmaceuticals undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Regeneron Pharmaceuticals can easily liquidate in the marketplace.Other Current Liab
Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 8th of June 2024, Tax Provision is likely to grow to about 584.1 M, while Sales General And Administrative To Revenue is likely to drop 0.26.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 4.7B | 5.6B | 7.1B | 7.4B | Cost Of Revenue | 2.4B | 1.6B | 883.7M | 927.9M |
Regeneron Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Regeneron Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regeneron Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 34.7B | |
Total Current Liabilities | 1.8B | 2.8B | 3.5B | 3.8B | 3.4B | 3.6B | |
Total Stockholder Equity | 11.1B | 11.0B | 18.8B | 22.7B | 26.0B | 27.3B | |
Property Plant And Equipment Net | 2.9B | 3.2B | 3.5B | 3.8B | 4.1B | 4.4B | |
Net Debt | (903.9M) | 502M | (185.9M) | (404.5M) | (27.1M) | (28.5M) | |
Retained Earnings | 7.4B | 10.9B | 19.0B | 23.3B | 27.3B | 28.6B | |
Cash | 1.6B | 2.2B | 2.9B | 3.1B | 2.7B | 2.9B | |
Non Current Assets Total | 4.2B | 4.4B | 4.9B | 7.1B | 13.6B | 14.3B | |
Non Currrent Assets Other | 531.8M | 328.9M | 555.2M | (4.7B) | 444.1M | 466.3M | |
Cash And Short Term Investments | 6.5B | 6.7B | 12.5B | 14.3B | 10.8B | 11.4B | |
Net Receivables | 2.7B | 4.1B | 6.0B | 5.3B | 5.7B | 6.0B | |
Common Stock Shares Outstanding | 114.6M | 115.1M | 112.2M | 113.5M | 113.7M | 75.4M | |
Liabilities And Stockholders Equity | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 34.7B | |
Non Current Liabilities Total | 1.9B | 3.3B | 3.2B | 2.7B | 3.7B | 3.9B | |
Other Current Assets | 959.3M | 1.2B | 332.4M | 933M | 386.6M | 203.9M | |
Other Stockholder Equity | 3.7B | 102.9M | (173.4M) | (404M) | (1.2B) | (1.1B) | |
Total Liab | 3.7B | 6.1B | 6.7B | 6.6B | 7.1B | 7.5B | |
Total Current Assets | 10.6B | 12.8B | 20.5B | 22.1B | 19.5B | 20.5B | |
Short Long Term Debt Total | 713.9M | 2.7B | 2.7B | 2.7B | 2.7B | 2.8B | |
Other Current Liab | 781.1M | 122.4M | 1.7B | 2.0B | 2.4B | 2.5B | |
Accounts Payable | 418.1M | 475.5M | 564M | 589.2M | 606.6M | 636.9M | |
Property Plant And Equipment Gross | 2.9B | 3.2B | 4.9B | 5.4B | 6.1B | 6.4B | |
Accumulated Other Comprehensive Income | 21.1M | 29.3M | (26.2M) | (238.8M) | (80.9M) | (76.9M) | |
Short Term Investments | 1.6B | 1.4B | 2.8B | 4.6B | 8.1B | 8.5B | |
Inventory | 1.4B | 1.9B | 2.0B | 2.4B | 2.6B | 2.7B | |
Other Liab | 889M | 635.5M | 515.3M | 707.8M | 814.0M | 854.7M | |
Other Assets | 913.3M | 2.8B | 555.2M | 747.6M | 859.7M | 902.7M | |
Property Plant Equipment | 2.9B | 3.2B | 3.5B | 3.8B | 4.3B | 4.5B | |
Current Deferred Revenue | 591.7M | 577.7M | 442M | 547.7M | 458.9M | 481.8M | |
Net Tangible Assets | 11.1B | 11.0B | 18.8B | 21.7B | 25.0B | 26.3B | |
Retained Earnings Total Equity | 7.4B | 10.9B | 19.0B | 23.3B | 26.8B | 28.1B | |
Long Term Debt Total | 713.9M | 2.0B | 2.0B | 2.0B | 2.3B | 2.4B | |
Capital Surpluse | 4.4B | 6.7B | 8.1B | 9.9B | 11.4B | 12.0B | |
Long Term Investments | 3.3B | 3.1B | 6.8B | 6.6B | 5.4B | 3.3B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Regeneron Stock
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share 33.83 | Revenue Per Share 122.574 | Quarterly Revenue Growth (0.01) | Return On Assets 0.0774 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.